Fibrinogen Dusart presenting as recurrent thromboses in the hepatic portal system

Yu Min Shen, Vinh Trang, Ravi Sarode, Stephen Brennan

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Dysfibrogenemias are characterized by the production of abnormally functioning fibrinogen, occurring in the presence of liver disease, medication toxicity, malignancy, or genetic mutation. Here, we report a patient with multiple, separate episodes of hepatic portal system thromboses associated with dysfibrinogenemia. Molecular studies identified the presence of a 554Arg→Cys mutation in the fibrinogen Aα gene, previously identified as Fibrinogen Dusart (also known as Fibrinogen Paris V and Fibrinogen Chapel Hill). This case further illustrates the association of this dysfibrinogenemia with a unique thrombophilic manifestation.

Original languageEnglish (US)
Pages (from-to)392-394
Number of pages3
JournalBlood Coagulation and Fibrinolysis
Volume25
Issue number4
DOIs
StatePublished - 2014

Fingerprint

Portal System
Fibrinogen
Thrombosis
Liver
Mutation
Liver Diseases
Genes
fibrinogen Dusard
Neoplasms

Keywords

  • Chapel Hill
  • Dusart
  • dysfibrinogenemia
  • fibrinogen
  • hypercoagulable state
  • Paris V
  • splanchnic vein thrombosis
  • thromboembolism

ASJC Scopus subject areas

  • Hematology

Cite this

Fibrinogen Dusart presenting as recurrent thromboses in the hepatic portal system. / Shen, Yu Min; Trang, Vinh; Sarode, Ravi; Brennan, Stephen.

In: Blood Coagulation and Fibrinolysis, Vol. 25, No. 4, 2014, p. 392-394.

Research output: Contribution to journalArticle

@article{7831cb2e856c4191b36309839aec9158,
title = "Fibrinogen Dusart presenting as recurrent thromboses in the hepatic portal system",
abstract = "Dysfibrogenemias are characterized by the production of abnormally functioning fibrinogen, occurring in the presence of liver disease, medication toxicity, malignancy, or genetic mutation. Here, we report a patient with multiple, separate episodes of hepatic portal system thromboses associated with dysfibrinogenemia. Molecular studies identified the presence of a 554Arg→Cys mutation in the fibrinogen Aα gene, previously identified as Fibrinogen Dusart (also known as Fibrinogen Paris V and Fibrinogen Chapel Hill). This case further illustrates the association of this dysfibrinogenemia with a unique thrombophilic manifestation.",
keywords = "Chapel Hill, Dusart, dysfibrinogenemia, fibrinogen, hypercoagulable state, Paris V, splanchnic vein thrombosis, thromboembolism",
author = "Shen, {Yu Min} and Vinh Trang and Ravi Sarode and Stephen Brennan",
year = "2014",
doi = "10.1097/MBC.0000000000000045",
language = "English (US)",
volume = "25",
pages = "392--394",
journal = "Blood Coagulation and Fibrinolysis",
issn = "0957-5235",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Fibrinogen Dusart presenting as recurrent thromboses in the hepatic portal system

AU - Shen, Yu Min

AU - Trang, Vinh

AU - Sarode, Ravi

AU - Brennan, Stephen

PY - 2014

Y1 - 2014

N2 - Dysfibrogenemias are characterized by the production of abnormally functioning fibrinogen, occurring in the presence of liver disease, medication toxicity, malignancy, or genetic mutation. Here, we report a patient with multiple, separate episodes of hepatic portal system thromboses associated with dysfibrinogenemia. Molecular studies identified the presence of a 554Arg→Cys mutation in the fibrinogen Aα gene, previously identified as Fibrinogen Dusart (also known as Fibrinogen Paris V and Fibrinogen Chapel Hill). This case further illustrates the association of this dysfibrinogenemia with a unique thrombophilic manifestation.

AB - Dysfibrogenemias are characterized by the production of abnormally functioning fibrinogen, occurring in the presence of liver disease, medication toxicity, malignancy, or genetic mutation. Here, we report a patient with multiple, separate episodes of hepatic portal system thromboses associated with dysfibrinogenemia. Molecular studies identified the presence of a 554Arg→Cys mutation in the fibrinogen Aα gene, previously identified as Fibrinogen Dusart (also known as Fibrinogen Paris V and Fibrinogen Chapel Hill). This case further illustrates the association of this dysfibrinogenemia with a unique thrombophilic manifestation.

KW - Chapel Hill

KW - Dusart

KW - dysfibrinogenemia

KW - fibrinogen

KW - hypercoagulable state

KW - Paris V

KW - splanchnic vein thrombosis

KW - thromboembolism

UR - http://www.scopus.com/inward/record.url?scp=84900411289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900411289&partnerID=8YFLogxK

U2 - 10.1097/MBC.0000000000000045

DO - 10.1097/MBC.0000000000000045

M3 - Article

C2 - 24384913

AN - SCOPUS:84900411289

VL - 25

SP - 392

EP - 394

JO - Blood Coagulation and Fibrinolysis

JF - Blood Coagulation and Fibrinolysis

SN - 0957-5235

IS - 4

ER -